Cargando…

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using the prespecified longitudinal systematic collection of plasma samples in the phase 1/2a LYM1002 trial (registered on www...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruscaggin, Alessio, di Bergamo, Lodovico Terzi, Spina, Valeria, Hodkinson, Brendan, Forestieri, Gabriela, Bonfiglio, Ferdinando, Condoluci, Adalgisa, Wu, Wei, Pirosa, Maria C., Faderl, Martin R., Koch, Ricardo, Schaffer, Michael, Alvarez, John D., Fourneau, Nele, Gerber, Bernhard, Stussi, Georg, Zucca, Emanuele, Balasubramanian, Sriram, Rossi, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759132/ https://www.ncbi.nlm.nih.gov/pubmed/34500472 http://dx.doi.org/10.1182/bloodadvances.2021004528

Ejemplares similares

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
por: Duault, Caroline, et al.
Publicado: (2021)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
por: Wieduwilt, Matthew J., et al.
Publicado: (2022)

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
por: Isaksen, Kathrine T., et al.
Publicado: (2021)

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
por: Mayerhoefer, Marius E., et al.
Publicado: (2022)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway
por: Butler, Miriam, et al.
Publicado: (2021)

ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1
por: Zhong, Wenbin, et al.
Publicado: (2022)

The molecular hallmarks of primary and secondary vitreoretinal lymphoma
por: Bonzheim, Irina, et al.
Publicado: (2022)

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
por: Koh, Min Jung, et al.
Publicado: (2022)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
por: Ren, Weicheng, et al.
Publicado: (2022)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
por: Harkins, R. Andrew, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia
por: Jiang, Chuang, et al.
Publicado: (2022)

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
por: Joelsson, Joel, et al.
Publicado: (2022)

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
por: Jensen, Paw, et al.
Publicado: (2022)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia
por: Laidou, Stamatia, et al.
Publicado: (2022)

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A-rearranged leukemia
por: Chen, Changya, et al.
Publicado: (2022)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iva4nn5g4c4m18khcoiga23l5h